



# Transparency notification FMR LLC.

Notification referring to situation on 27 July 2020

Threshold crossed: 3%Latest holding: 3.63 %

Brussels (Belgium), 30 July 2020 – 20:00 (CEST) – regulated information

## 1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, U.S.A.), dated 28 July 2020.

FMR LLC., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, one of its affiliates (in particular Fidelity Management & Research Company LLC.), has crossed the 3% threshold on an individual basis on 27 July 2020.

On 27 July 2020, Fidelity Management & Research Company LLC. owned 6 086 793 UCB shares with voting rights (versus 4 978 323 UCB shares in its previous notification), representing 3.13% of the total number of shares issued by the company (194 505 658) (versus 2.56% in its previous notification).

On 27 July 2020, FMR LLC. (taking into account the holding of its affiliates) owned 7 060 944 UCB shares with voting rights (versus 5 870 985 UCB shares in its previous notification), representing 3.63% of the total number of shares issued by the company (194 505 658) (versus 3.02% in its previous notification).

### 2. Content of the notification

- Reason for the notification: Acquisition or disposal of voting securities or voting rights.
- **Notification by**: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:

Name	Address (for legal entities)
IEMRIIC:	The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801

• Date on which the threshold is crossed: 27 July 2020





• Threshold crossed (in %): 3%

• **Denominator**: 194 505 658.

Notified details:

A) Voting rights	Previous notification	After the transaction				
	# of voting rights	# of voti	ng rights	% of voting rights		
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
FMR LLC	0	0		0.00%		
FIAM LLC	287,874	344,879		0.18%		
Fidelity Institutional Asset Management Trust Company	135,866	161,950		0.08%		
FMR Investment Management (UK) Limited	468,922	467,322		0.24%		
Fidelity Management & Research Company LLC	4,978,323	6,086,793		3.13%		
Subtotal	5,870,985	7,060,944		3.63%		
TOTAL		7,060,944	0	3.63%	0.00%	

B) Equivalent financial instruments	After the transaction							
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement		
TOTAL			0	0.00%				
	TOTAL (A & B)			# of voting rights	% of voting rights			
CALCULATE			7,060,944	3.63%				

• Chain of controlled undertakings through which the holding is effectively held:



Fidelity Institutional Asset Management Trust Company and FIAM LLC are controlled by FIAM Holdings LLC, FIAM Holdings LLC is controlled by FMR LLC

Fidelity Management & Research Company LLC is controlled by FMR LLC FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC FMR LLC is not a controlled entity.

#### 3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following <u>link</u>.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

#### **Investor Relations**

Antje Witte, Investor Relations, UCB T +32 2 559 94 14, antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 95 88, isabelle.ghellynck@ucb.com

#### **About UCB**

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

